Humphreys Mitchell R, Miller Nicole L, Handa Shelly E, Terry Colin, Munch Larry C, Lingeman James E
Department of Urology, Mayo Clinic, Phoenix, Arizona, USA.
J Urol. 2008 Dec;180(6):2431-5; discussion 2435. doi: 10.1016/j.juro.2008.08.019. Epub 2008 Oct 19.
Generally treatment decisions for benign prostatic hyperplasia are based on prostate size and surgeon experience. Prostates greater than 100 gm often require open surgery. However, less invasive options are available. Randomized, controlled trials have demonstrated that holmium laser enucleation of the prostate is a viable and effective treatment for benign prostatic hyperplasia. We examined the outcome of holmium laser enucleation of the prostate based on prostate size.
We retrospectively reviewed the records of all patients in our institutional review board approved database who underwent holmium laser enucleation of the prostate from January 1999 to October 2006. Patients were divided into 3 cohorts based on preoperative transrectal ultrasound prostate measurements, including less than 75, 75 to 125 and more than 125 gm. Patients with prostate cancer were excluded from study. Demographic, laboratory, operative, preoperative and postoperative data were obtained.
As prostate size increased, so did prostate specific antigen, and the urinary retention and enucleation rates. Hospitalization, catheterization, preoperative and postoperative outcomes were similar among the groups. On linear regression the decrease in prostate specific antigen highly correlated with the amount of tissue removed (p <0.0001). The complication rate was similar among the treatment groups. All patients did equally well in terms of postoperative urinary function independent of prostate size.
Holmium laser enucleation of the prostate is a safe and effective minimally invasive treatment for benign prostatic hyperplasia. It improved patient prostate specific antigen, American Urological Association symptom score and maximum urinary flow rate independent of the amount of benign prostatic hyperplasia present. Our results demonstrate the advantage of holmium laser enucleation of the prostate to treat all prostates regardless of size with favorable and equivalent outcomes.
一般来说,良性前列腺增生的治疗决策基于前列腺大小和外科医生的经验。前列腺重量超过100克的患者通常需要进行开放手术。然而,也有侵入性较小的治疗选择。随机对照试验表明,钬激光前列腺剜除术是治疗良性前列腺增生的一种可行且有效的方法。我们根据前列腺大小研究了钬激光前列腺剜除术的治疗效果。
我们回顾性分析了1999年1月至2006年10月期间在我们机构审查委员会批准的数据库中接受钬激光前列腺剜除术的所有患者的记录。根据术前经直肠超声测量的前列腺大小,将患者分为3组,包括小于75克、75至125克和大于125克。前列腺癌患者被排除在研究之外。获取了患者的人口统计学、实验室检查、手术、术前和术后数据。
随着前列腺大小的增加,前列腺特异性抗原、尿潴留率和剜除率也随之增加。各组之间的住院时间、导尿时间、术前和术后结果相似。线性回归分析显示,前列腺特异性抗原的下降与切除的组织量高度相关(p<0.0001)。各治疗组的并发症发生率相似。所有患者术后的排尿功能均良好,与前列腺大小无关。
钬激光前列腺剜除术是治疗良性前列腺增生的一种安全有效的微创治疗方法。无论存在的良性前列腺增生量多少,它都能改善患者的前列腺特异性抗原、美国泌尿外科学会症状评分和最大尿流率。我们的结果表明,钬激光前列腺剜除术治疗所有大小的前列腺均具有优势,疗效良好且相当。